JP2015536999A - 攻撃性の治療法 - Google Patents

攻撃性の治療法 Download PDF

Info

Publication number
JP2015536999A
JP2015536999A JP2015542030A JP2015542030A JP2015536999A JP 2015536999 A JP2015536999 A JP 2015536999A JP 2015542030 A JP2015542030 A JP 2015542030A JP 2015542030 A JP2015542030 A JP 2015542030A JP 2015536999 A JP2015536999 A JP 2015536999A
Authority
JP
Japan
Prior art keywords
dose
morindon
receptor
human subject
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015542030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536999A5 (enExample
Inventor
ケニス ハッム，ピーエイチ．ディー．，アダム
ケニス ハッム，ピーエイチ．ディー．，アダム
Original Assignee
スパーナス ファーマシューティカルズ インコーポレイテッド
スパーナス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スパーナス ファーマシューティカルズ インコーポレイテッド, スパーナス ファーマシューティカルズ インコーポレイテッド filed Critical スパーナス ファーマシューティカルズ インコーポレイテッド
Publication of JP2015536999A publication Critical patent/JP2015536999A/ja
Publication of JP2015536999A5 publication Critical patent/JP2015536999A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015542030A 2012-11-13 2013-11-13 攻撃性の治療法 Pending JP2015536999A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261725883P 2012-11-13 2012-11-13
US61/725,883 2012-11-13
US201261727570P 2012-11-16 2012-11-16
US61/727,570 2012-11-16
PCT/US2013/069863 WO2014078394A1 (en) 2012-11-13 2013-11-13 Method of treatment of aggression

Publications (2)

Publication Number Publication Date
JP2015536999A true JP2015536999A (ja) 2015-12-24
JP2015536999A5 JP2015536999A5 (enExample) 2016-08-04

Family

ID=49681174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542030A Pending JP2015536999A (ja) 2012-11-13 2013-11-13 攻撃性の治療法

Country Status (7)

Country Link
US (1) US20140135326A1 (enExample)
EP (2) EP3524251A1 (enExample)
JP (1) JP2015536999A (enExample)
AU (2) AU2013344920A1 (enExample)
CA (1) CA2888725A1 (enExample)
MX (1) MX2015005937A (enExample)
WO (1) WO2014078394A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019520315A (ja) * 2016-04-29 2019-07-18 スパーナス ファーマシューティカルズ インコーポレイテッド 衝動的攻撃性を監視、診断、及び治療する方法、システム、及びキット

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006463A (es) 2008-12-19 2011-07-20 Supernus Pharmaceuticals Inc Metodo de tratamiento de agresion.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080603A2 (en) * 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Method of treatment of aggression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
US6613763B2 (en) * 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
WO2004069339A1 (en) * 2003-01-29 2004-08-19 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
JP6063377B2 (ja) * 2010-03-31 2017-01-18 スパーナス ファーマシューティカルズ インコーポレイテッド Ｃｎｓ化合物の安定化製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080603A2 (en) * 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
JP2012512897A (ja) * 2008-12-19 2012-06-07 スパーナス ファーマシューティカルズ インコーポレイテッド 攻撃性を治療する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. CHILD ADOLESC. PSYCHOPHARMACOL., 2012 APR, VOL.22, NO.2, PP.102-111, JPN6017010227, ISSN: 0003524395 *
J. CLIN. PSYCHIATRY, 1985, VOL.46, NO.8 PT.2, PP.20-25, JPN6017010228, ISSN: 0003524396 *
PSYCHOPHARMACOL. BULL., 1981, VOL.17, NO.1, PP.125-127, JPN6017010229, ISSN: 0003524397 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019520315A (ja) * 2016-04-29 2019-07-18 スパーナス ファーマシューティカルズ インコーポレイテッド 衝動的攻撃性を監視、診断、及び治療する方法、システム、及びキット
JP2022017408A (ja) * 2016-04-29 2022-01-25 スパーナス ファーマシューティカルズ インコーポレイテッド 衝動的攻撃性を監視、診断、及び治療する方法、システム、及びキット

Also Published As

Publication number Publication date
US20140135326A1 (en) 2014-05-15
AU2013344920A1 (en) 2015-04-30
CA2888725A1 (en) 2014-05-22
AU2018202636A1 (en) 2018-05-10
WO2014078394A1 (en) 2014-05-22
EP2919787A1 (en) 2015-09-23
MX2015005937A (es) 2015-09-08
EP3524251A1 (en) 2019-08-14

Similar Documents

Publication Publication Date Title
El-Bayoumi et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study
CA2923685C (en) Application of r-ketamine and salt thereof as pharmaceuticals
Narayan et al. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic
JP6316480B2 (ja) 攻撃性を治療する方法
Karbalaee et al. Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
JP2015536999A (ja) 攻撃性の治療法
Livianos et al. Is melatonin an adjunctive stabilizer?
Zhang et al. MPC-n (IgG) improves long-term cognitive impairment in the mouse model of repetitive mild traumatic brain injury
Willien Sulfanilamide therapy in meningococcic meningitis
Zhang et al. M2 microglia-derived small extracellular vesicles modulate NSC fate after ischemic stroke via miR-25-3p/miR-93-5p-TGFBR/PTEN/FOXO3 axis
Mogi et al. Mirtazapine as an alternative for selective-serotonin-reuptake-inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone.
US20220401391A1 (en) Methods and compositions for treating pain
Ge et al. miR-21, a potential therapeutic target of alleviating blood-brain barrier damage after traumatic brain injury
Chee et al. The use of intravenous immunoglobulin in autoimmune bullous diseases
Wang et al. Diagnosis and treatment of comorbidities of Tourette's syndrome and bipolar disorder in a 10-year-old boy
Wu et al. Triptolide promotes autophagy to protect renal tubular epithelial cells from high glucose-induced macrophage-derived exosomes incubation
Litzenburger et al. 32 Safety, pharmacokinetics and pharmacodynamics of BI 705564, a covalent inhibitor of brutons tyrosine kinase in phase 1 clinical trials in healthy volunteers
Sperling et al. Potential for Therapeutic Alteration of the Underlying Biology of Epilepsy
Holland et al. O51. Beyond C4: Analysis of the Complement Gene Pathway Shows Enrichment for IQ in Patients With Schizophrenia and Healthy Controls
Kremmidiotis et al. P. 4. a. 005 Pharmacodynamic effects of single oral doses of the novel anxiolytic compound BNC210 in healthy male volunteers
Tamir et al. KPT-350, a selective inhibitor of nuclear export (SINE) compound, shows efficacy in the mouse pilocapine model of temporal lobe epilepsy

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20151007

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180227